FTXHFirst Trust Nasdaq Pharmaceuticals ETF
Seeks investment results that correspond generally to the price and yield of the Nasdaq US Smart Pharmaceuticals Index.
By First Trust · Launched 2016
Annual Cost
0.60%
#3,235 of 5,861 · average
Fund Size
$36M
#3,971 of 5,861 · small
Return (1Y)Goal
+49.6%
Track Record
9 years
#1,451 of 5,861 · established
Performance
Total-return NAV · USDGrowth of $10,000
$14,865+48.7%
Total-return NAV, USD. Net of fund fees, before tax.
What's inside
How Beacon categorizes this fundAsset class
EquityRegion
North americaCap
Multi cap
Strategy
Index tracking
Sector
Health careFocus
Biotech & Genomics
Index tracked
Nasdaq US Smart Pharmaceuticals Index
What it actually holds
By weightConcentration
Top 10 holdings = 54.1% of fundmoderately concentrated
Johnson & Johnson
7.5%
Bristol-Myers Squibb Company
7.4%
Merck & Co., Inc
7.4%
AbbVie Inc.
7.1%
Eli Lilly & Co.
6.6%
Pfizer Inc.
3.8%
Regeneron Pharmaceuticals, Inc.
3.7%
Biogen Inc
3.6%
Gilead Sciences Inc.
3.5%
Cardinal Health, Inc.
3.5%
Asset allocation
Stocks
99.9%
Cash
0.1%
By sector
Healthcare
100.0%
Risk profile
Last 12 months · Sharpe & Sortino need 3+ yearsVolatility (1Y)
17.2%Moderate
Year-on-year price swings
Max drawdown
-32.0%Severe
Worst peak-to-trough loss
Sharpe (3Y)
0.71Decent risk-adjusted returns
Sortino (3Y)
1.03Good downside protection
Listing
- Exchange
- NASDAQ Global Select Market
Full fund details
- Objective
- Seeks investment results that correspond generally to the price and yield of the Nasdaq US Smart Pharmaceuticals Index.
- Strategy
- Invests at least 90% of net assets in securities that comprise the Nasdaq US Smart Pharmaceuticals Index using an indexing investment approach. The Index provides exposure to the top factor-ranked securities from U.S. pharmaceutical and biotechnology companies, with a market capitalization-weighted structure.
- Inception date
- September 20, 2016
- Fund family
- First Trust
Similar funds
Same asset class, closest by strategy & exposureWhat's next?
You've looked at FTXH. Save it to your watchlist to weigh it against other funds, then turn your shortlist into a portfolio.
Data updated on 2026-08-04